Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study

Aim. To investigate the efficacy and safety of combined glimepiride and metformin therapy in patients with type 2 diabetes mellitus (T2DM). Materials and methods. A multi-centre, open-label, prospective, observational study was conducted. A total of 1200 patients with T2DM inadequately controlled...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalya Vladislavovna Zaytseva, Ivona Renata Jarek-Martynova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2015
Materias:	glycated haemoglobin diabetes mellitus glimepiride metformin Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/01731ff43c654097a49be8c4ae30be69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:01731ff43c654097a49be8c4ae30be69
record_format	dspace
spelling	oai:doaj.org-article:01731ff43c654097a49be8c4ae30be692021-11-14T09:00:19ZEvaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study2072-03512072-037810.14341/DM2015284-88https://doaj.org/article/01731ff43c654097a49be8c4ae30be692015-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/7096https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378Aim. To investigate the efficacy and safety of combined glimepiride and metformin therapy in patients with type 2 diabetes mellitus (T2DM). Materials and methods. A multi-centre, open-label, prospective, observational study was conducted. A total of 1200 patients with T2DM inadequately controlled with metformin, glimepiride or combination of metformin + glimepiride were enrolled. Change in serum glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial blood glucose (PPG) levels; weight; waist circumference and hypoglycemic episodes were evaluated. Results. Baseline HbA1c levels (8.24% ? 0.42%) were significantly reduced after 12 weeks of treatment (7.48% ? 0.48%) and at the end of the study. (6.88% ? 0.56%). Target HbA1c levels (?7%) were achieved in 65.1% of patients at the final visit at 24 weeks. FPG and PPG levels decreased by 1.45 ? 1.14 mmol/l and 2.17 ? 1.27 mmol/l respectively (p < 0.001). No severe hypoglycemic events were reported. Body mass index reduced by 0.85 ? 1.28 kg/m2 (p < 0.001). Conclusion. . Combined glimepiride and metformin therapy significantly improved long-term glycemic control in patients with T2DM during the period of 24 weeks. without additional risk of hypoglycemic events or weight gain.Natalya Vladislavovna ZaytsevaIvona Renata Jarek-MartynovaEndocrinology Research Centrearticleglycated haemoglobindiabetes mellitusglimepiridemetforminNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 18, Iss 2, Pp 84-88 (2015)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	glycated haemoglobin diabetes mellitus glimepiride metformin Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	glycated haemoglobin diabetes mellitus glimepiride metformin Nutritional diseases. Deficiency diseases RC620-627 Natalya Vladislavovna Zaytseva Ivona Renata Jarek-Martynova Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
description	Aim. To investigate the efficacy and safety of combined glimepiride and metformin therapy in patients with type 2 diabetes mellitus (T2DM). Materials and methods. A multi-centre, open-label, prospective, observational study was conducted. A total of 1200 patients with T2DM inadequately controlled with metformin, glimepiride or combination of metformin + glimepiride were enrolled. Change in serum glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), and postprandial blood glucose (PPG) levels; weight; waist circumference and hypoglycemic episodes were evaluated. Results. Baseline HbA1c levels (8.24% ? 0.42%) were significantly reduced after 12 weeks of treatment (7.48% ? 0.48%) and at the end of the study. (6.88% ? 0.56%). Target HbA1c levels (?7%) were achieved in 65.1% of patients at the final visit at 24 weeks. FPG and PPG levels decreased by 1.45 ? 1.14 mmol/l and 2.17 ? 1.27 mmol/l respectively (p < 0.001). No severe hypoglycemic events were reported. Body mass index reduced by 0.85 ? 1.28 kg/m2 (p < 0.001). Conclusion. . Combined glimepiride and metformin therapy significantly improved long-term glycemic control in patients with T2DM during the period of 24 weeks. without additional risk of hypoglycemic events or weight gain.
format	article
author	Natalya Vladislavovna Zaytseva Ivona Renata Jarek-Martynova
author_facet	Natalya Vladislavovna Zaytseva Ivona Renata Jarek-Martynova
author_sort	Natalya Vladislavovna Zaytseva
title	Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
title_short	Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
title_full	Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
title_fullStr	Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
title_full_unstemmed	Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study
title_sort	evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. results of russian observational study
publisher	Endocrinology Research Centre
publishDate	2015
url	https://doaj.org/article/01731ff43c654097a49be8c4ae30be69
work_keys_str_mv	AT natalyavladislavovnazaytseva evaluationoffixeddosecombinationofglimepirideandmetformininpatientswithtype2diabetesresultsofrussianobservationalstudy AT ivonarenatajarekmartynova evaluationoffixeddosecombinationofglimepirideandmetformininpatientswithtype2diabetesresultsofrussianobservationalstudy
_version_	1718429567666880512

Evaluation of fixed dose combination of glimepiride and metformin in patients with type 2 diabetes. Results of Russian observational study

Ejemplares similares